Results 111 to 120 of about 137,068 (205)

Liver Metabolomic Profiling Reveals Distinct Signatures Between Steatosis and Metabolic Dysfunction-Associated Steatohepatitis. [PDF]

Liver Int
Palomurto S, Flam E, Kaminska D, Virtanen KA, Kärjä V, Käkelä P, Pajukanta P, Eberlé D, Haas JT, Raverdy V, Caiazzo R, Pattou F, Staels B, Pihlajamäki J, Männistö V.   +14 more
europepmc   +1 more source

Efficacy and safety of endoscopic sleeve gastroplasty for patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and trial sequential meta-analysis. [PDF]

Syst Rev
Sun SP, Chen C, Min H.
europepmc   +1 more source

Rice Bran Attenuates Liver Fibrosis Caused by Vitamin E Deficiency in the Pre-Aging Stage. [PDF]

Yonago Acta Med
Takahashi Y, Kato Y, Horikoshi Y, Hanaki T, Ueki M, Nakaso K.   +5 more
europepmc   +1 more source

The Elucidating Pathways of Steatohepatitis (EPoS) staging system: A reproducible 7-tiered fibrosis scoring system in MASLD. [PDF]

JHEP Rep
Tiniakos DG, Bedossa P, Arola J, Davies S, Gouw ASH, Guido M, Lackner C, Schirmacher P, Terracciano L, Blain A, Wonders K, Anstee QM, Ratziu V, Paradis V.   +13 more
europepmc   +1 more source

Pancreatic steatosis is not associated with advanced steatohepatitis or fibrosis in metabolic dysfunction-associated steatotic liver disease. [PDF]

World J Gastroenterol
Heymann G, Rahman S, Kats D, Banini BA, Gaddam S, Aslanian E, Boateng S, Israel G, Muniraj T.   +8 more
europepmc   +1 more source

Epidemiological trends of NASH-related liver cancer in young and middle-aged populations: A global disease burden analysis from 1990 to 2021. [PDF]

Medicine (Baltimore)
Shang H, Chu B, Yu X, Tang N, Chen Z.
europepmc   +1 more source

AI portal tract detection and characterisation for a regional analysis of steatosis and inflammation in MASLD, MASH and AIH. [PDF]

J Clin Pathol
Windell D, Magness A, Beyer C, Brears HT, Larkin S, Hobson K, Aljabar P, Fleming K, Fryer E, Kendall TJ, Kainth R, Wakefield P, Langford CR, Bedossa P, Goldin R.   +14 more
europepmc   +1 more source

Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis. [PDF]

Syst Rev
Wang MJ, Jiang YN, Li PP, Wu YJ.
europepmc   +1 more source

The role of tryptophan-AhR signaling in the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD): implications for therapeutic strategies. [PDF]

Front Immunol
Zhao Y, Cheng S, Liang J, Yu G.
europepmc   +1 more source

Metabolic dysfunction-associated fatty liver disease: an update. [PDF]

Aust Prescr
O'Halloran R, Adams LA, Deed G, Lubel JS.   +3 more
europepmc   +1 more source